AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally.
The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products.
The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers.
It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names.
The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Country | United States |
IPO Date | Mar 19, 2001 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 391 |
CEO | James W. Green |
Contact Details
Address: 84 October Hill Road Holliston, Massachusetts United States | |
Website | https://www.harvardbioscience.com |
Stock Details
Ticker Symbol | HBIO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001123494 |
CUSIP Number | 416906105 |
ISIN Number | US4169061052 |
Employer ID | 04-3306140 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
James W. Green | President, Chief Executive Officer & Chairman |
Jennifer Cote CPA, CGMA | Chief Financial Officer & Treasurer |
David Sirois | Director of Corporate Accounting & SEC Reporting |
John J. Fry J.D. | Chief Legal Counsel & Corporation Secretary |
Kathryn Flynn | Corporate Controller |
Lori Packer | Vice President of Global People Operations |
Ryan Wallace | Senior Vice President of Global Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 31, 2024 | 4 | Filing |
Dec 31, 2024 | 4 | Filing |
Dec 06, 2024 | S-3 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Aug 08, 2024 | 10-Q | Quarterly Report |
Aug 08, 2024 | 8-K | Current Report |
Jun 14, 2024 | 4 | Filing |
Jun 07, 2024 | 4 | Filing |